PIONEERING FIRST-IN-CLASS ANTAGONISTS OF THE RETINOID NUCLEAR RECEPTOR PATHWAY FOR UNMET MEDICAL NEEDS
Kayothera specializes in inhibiting two of the last remaining nuclear receptors pathways to be drugged – the retinoid and rexinoid nuclear receptors. These pathways are clinically validated to drive adverse cardiometabolic and cancer outcomes, yet have no available inhibitors – until now.
Kayothera’s unique approach blocks the formation of the retinoid or rexinoid nuclear ligands with novel, orally-available small molecules that have proven to be safe and effective therapies. We are developing these medicines to provide patients with new options for managing diabetes, obesity and additional unmet medical needs.
LATEST NEWS
Kayothera, Inc. Nominates KAYO-1732, a First-In-Class, Oral Inhibitor of the Retinoid Nuclear Receptor Pathway in Type 2 Diabetes and Cardiometabolic Indications as a Development Candidate
Seattle, WA — September 23, 2025 – Kayothera, Inc. (“Kayothera”), a preclinical therapeutics company developing first-in-class, small molecule inhibitors of the retinoid nuclear receptor pathway, today announces that it has selected KAYO-1732 as a drug development...
Kayothera Named as a Winner of the American Diabetes Association’s Innovation Challenge to Transform Type 2 Diabetes Care
Seattle, WA — June 21, 2025, Kayothera, Inc., a preclinical-stage therapeutics company pioneering first-in-class, oral inhibitors of the retinoid nuclear receptor pathway, today announced that it has been recognized as one of the winners of the American Diabetes...
Kayothera Announces Expansion of the Scientific Advisory Board
Yibin Kang, PhD, chairs Scientific Advisory Board that includes experts in translational and early-phase clinical development activities Seattle, WA — October 22, 2024, Kayothera, Inc., a preclinical-stage therapeutics company developing first-in-class, oral, small...
Kayothera Announces New Appointments to Board of Directors
Bruce L.A. Carter, PhD, and Paul Sekhri join Board of Directors, adding drug development and operating experience Recent board additions highlight Kayothera's evolution into pipeline-focused organization with meaningful translational efforts Seattle, WA — October 14,...
The pathogenic role of retinoid nuclear receptor signaling in cancer and metabolic syndromes
Review | Cancer Focus| August 12 2024 In Special Collection: Mechanisms and Models of Cancer 2024 Mark Esposito, John K. Amory, Yibin Kang J Exp Med (2024) 221 (9): e20240519. https://doi.org/10.1084/jem.20240519
Join us at BioNJ BioPartnering
Join our Co-Founder Dr. Mark Esposito as he shares an update on Kayothera at BioNJ BioPartnering on May 14th.
Join us at Life Science Innovation Northwest 2024
Join our Co-Founder Dr. Mark Esposito as he shares an update on Kayothera at Life Science Innovation Northwest (LSINW) 2024 on April 18th at 11:05 AM - 12:15 PM.
KayoThera, Inc. Nominates First-in-Class, Oral Inhibitor of the Retinoid Pathway in Genetically Defined Oncology Indications as a Development Candidate
Unique safety profile positions KAYO-1609 as the first retinoid pathway inhibitor to enter Investigational New Drug (IND)-enabling studies Company expects to file IND application with the U.S. Food & Drug Administration (FDA) by the end of 2024 Seattle, WA —...
Washington state backs AI-driven cancer diagnostics and other startup projects
Washington state backs AI-driven cancer diagnostics and other startup projects – GeekWire
KayoThera, Inc. Strengthens Financial Position with $5.2 Million in Grant and Expanded Series A Funding, Bringing Total Financial Support to $14 Million
New funding comprised of grants from the National Institutes of Health, The Andy Hill Cancer Research Endowment (CARE) Fund, and additional Equity Funding Additional funding will support advancement of KayoThera’s development programs in diabetes and oncology...